医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (8): 1153-1156    DOI: 10.3969/j.issn.1671-7171.2022.08.010
  论著 本期目录 | 过刊浏览 | 高级检索 |
参芪地黄汤对系膜增生性肾小球肾炎大鼠的作用及对p38MAPK/NF-κB信号通路的影响
王生辉1, 赵强2**
1.北京中医药大学孙思邈医院中医内科,陕西 铜川 727000;
2.陕西省安康市中医医院急诊科,陕西 安康 725000
Protection of Shenqi Dihuang Decoction on Mesangial Proliferative Glomerulonephritis Rats and Its Effect on p38MAPK/NF-κB Signal Pathway
WANG Sheng-hui, ZHAO Qiang
Beijing University of Chinese Medicine,Sun Simiao Hospital,Tongchuan Shaanxi 727000
全文: PDF (1679 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨参芪地黄汤对系膜增生性肾小球肾炎(MsPGN)大鼠的保护作用及对38丝裂原激活蛋白激酶/核转录因子Kappa B(p38MAPK/NF-κB)通路的影响。【方法】将40只大鼠随机分为假手术组、模型组及参芪地黄汤低剂量组和高剂量组,每组10只,采用胃肠道综合免疫法建立MsPGN大鼠模型(假手术组大鼠麻醉后仅暴露左肾,其余操作同模型组),其中参芪地黄汤低剂量组、高剂量组大鼠于模型建立成功后分别给予参芪地黄汤生药量(1.4 mg/mL、2.8 mg/mL溶液)10 mL/(kg·d)灌胃给药(连续4周),假手术组、模型组大鼠同时间灌胃等量生理盐水。检测各组尿液中的24 h尿蛋白及血尿素氮、血肌酐含量。ELISA法检测各组大鼠肾脏组织中白介素-8(IL-8)、肿瘤坏死因子α(TNF-α)水平;免疫印迹法检测各组大鼠肾脏组织中p38MAPK/NF-κB通路蛋白(p38MAPK、p-p38MAPK、NF-κB p65)水平。【结果】与假手术组比较,模型组及低剂量组、高剂量组大鼠24 h尿蛋白、尿素氮、血肌酐水平及肾组织中IL-8、TNF-α水平、p-p38MAPK/p38MAPK、NF-κB p65蛋白水平均升高(P<0.05);与模型组比较,低剂量组、高剂量组大鼠24 h尿蛋白、尿素氮、血肌酐水平及肾组织中IL-8、TNF-α水平、p-p38MAPK/p38MAPK、NF-κB p65蛋白水平均降低(P<0.05);与低剂量组比较,高剂量组大鼠各指标水平均降低(P<0.05)。【结论】参芪地黄汤对MsPGN大鼠有保护作用,可能是通过抑制p38MAPK/NF-κB通路活化,进而抑制肾脏组织炎症反应实现。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
王生辉
赵强
关键词 肾小球肾炎, 膜增生性/中药疗法大鼠疾病模型, 动物MAP激酶信号系统    
Abstract:【Objective】To investigate protective effect of Shenqi Dihuang decoction on mesangial proliferative glomerulonephritis (MsPGN) rats and its effect on 38 mitogen-activated protein kinase/nuclear transcription factor Kappa B (p38MAPK/NF-κB) pathway. 【Methods】Forty rats were randomly divided into the sham operation group,MsPGN model group and low and high dose groups of shenqi dihuang decoction,with 10 rats in each group. The rats in the sham-operated group were exposed to the left kidney only,and the rest were the same as those in the model group. The rats in the MsPGN group were exposed to the left kidney only after anesthesia,the rats in the low and high dose groups were given 10 mL/(kg·d) of shenqi dihuang decoction (1.4 mg/mL and 2.8 mg/mL solution) for 4 weeks after the MsPGN model was established,rats in the sham operation group and model group were given the same amount of normal saline at the same time. The 24 h urine protein,urea nitrogen and blood creatinine were measured. The levels of IL-8 and TNF-α in renal tissues were detected by ELISA,and p38MAPK/NF-κB pathway proteins (p38MAPK,p-p38MAPK,NF-κB p65) were detected by Western blotting.【Results】Compared with the sham operation group,the levels of 24 h urinary protein,urea nitrogen,serum creatinine,IL-8,TNF-α,p-p38MAPK/p38MAPK and NF-κB p65 in the model group and Shenqi Dihuang decoction group were all increased (P<0.05). Compared with the model group,the levels of 24 h urinary protein,urea nitrogen,serum creatinine,IL-8,TNF-α,p-p38MAPK/p38MAPK and NF-κB p65 in the low and high dose groups were decreased (P<0.05). Compared with the low-dose group,the levels of all indexes in the high dose group were decreased (P<0.05). 【Conclusion】The protective effect of Shenqi Dihuang decoction on MsPGN rats may be realized by inhibiting the activation of p38MAPK/NF-κB pathway and thus inhibiting the inflammatory reaction of renal tissue.
Key wordsGlomerulonephritis, Membranoproliferative/ZD    Rats    Disease Models, Animal    MAP Kinase Signaling System
收稿日期: 2022-01-17     
中图分类号:  R692.31  
基金资助:安康市科技计划项目(2018-J-02)
通讯作者: **E-mail:3263183894@qq.com   
引用本文:   
王生辉, 赵强. 参芪地黄汤对系膜增生性肾小球肾炎大鼠的作用及对p38MAPK/NF-κB信号通路的影响[J]. 医学临床研究, 2022, 39(8): 1153-1156.
WANG Sheng-hui, ZHAO Qiang. Protection of Shenqi Dihuang Decoction on Mesangial Proliferative Glomerulonephritis Rats and Its Effect on p38MAPK/NF-κB Signal Pathway. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1153-1156.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.08.010     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I8/1153
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn